Aspirin/pantoprazole - GlaxoSmithKline

Drug Profile

Aspirin/pantoprazole - GlaxoSmithKline

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Gastric antisecretories; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 12 Jul 2013 GlaxoSmithKline plans a phase I trial in Healthy volunteers in India (NCT01847404)
  • 01 Jul 2013 Preclinical trials in NSAID-induced ulcer in India (PO)
  • 31 May 2013 GlaxoSmithKline completes a phase I trial in healthy volunteers in India (NCT01847404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top